|
|
|
|
-
Research
Dr. Spruck studies the roles of ubiquitin-dependent proteolysis and cell cycle proteins in the regulation of cell division.
-
Biography
Charles Spruck earned his Ph.D. in molecular biology at the University of Southern California.
Development and validation of a method for profiling post-translational modification activities using protein microarrays.
Del Rincón SV, Rogers J, Widschwendter M, Sun D, Sieburg HB, Spruck C
PLoS One. 2010;5(6):e11332
Control of iron homeostasis by an iron-regulated ubiquitin ligase.
Vashisht AA, Zumbrennen KB, Huang X, Powers DN, Durazo A, Sun D, Bhaskaran N, Persson A, Uhlen M, Sangfelt O, Spruck C, Leibold EA, Wohlschlegel JA
Science. 2009 Oct 30;326(5953):718-21
FBXW7/hCDC4 is a general tumor suppressor in human cancer.
Akhoondi S, Sun D, von der Lehr N, Apostolidou S, Klotz K, Maljukova A, Cepeda D, Fiegl H, Dafou D, Dofou D, Marth C, Mueller-Holzner E, Corcoran M, Dagnell M, Nejad SZ, Nayer BN, Zali MR, Hansson J, Egyhazi S, Petersson F, Sangfelt P, Nordgren H, Grander D, Reed SI, Widschwendter M, Sangfelt O, Spruck C
Cancer Res. 2007 Oct 1;67(19):9006-12
Requirement of Cks2 for the first metaphase/anaphase transition of mammalian meiosis.
Spruck CH, de Miguel MP, Smith AP, Ryan A, Stein P, Schultz RM, Lincoln AJ, Donovan PJ, Reed SI
Science. 2003 Apr 25;300(5619):647-50
A CDK-independent function of mammalian Cks1: targeting of SCF(Skp2) to the CDK inhibitor p27Kip1.
Spruck C, Strohmaier H, Watson M, Smith AP, Ryan A, Krek TW, Reed SI
Mol Cell. 2001 Mar;7(3):639-50
Recent Options
miR-27a regulation of SCF(Fbw7) in cell division control and cancer.
Spruck C
Cell Cycle. 2011 Oct 1;10(19):3232-3
Cyclin-dependent kinase subunit (Cks) 1 or Cks2 overexpression overrides the DNA damage response barrier triggered by activated oncoproteins.
Liberal V, Martinsson-Ahlzén HS, Liberal J, Spruck CH, Widschwendter M, McGowan CH, Reed SI
Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2754-9
Inactivation of FBXW7/hCDC4-β expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer.
Akhoondi S, Lindström L, Widschwendter M, Corcoran M, Bergh J, Spruck C, Grandér D, Sangfelt O
Breast Cancer Res. 2010;12(6):R105
Development and validation of a method for profiling post-translational modification activities using protein microarrays.
Del Rincón SV, Rogers J, Widschwendter M, Sun D, Sieburg HB, Spruck C
PLoS One. 2010;5(6):e11332
Control of iron homeostasis by an iron-regulated ubiquitin ligase.
Vashisht AA, Zumbrennen KB, Huang X, Powers DN, Durazo A, Sun D, Bhaskaran N, Persson A, Uhlen M, Sangfelt O, Spruck C, Leibold EA, Wohlschlegel JA
Science. 2009 Oct 30;326(5953):718-21
SCF(Fbxw7/hCdc4) targets cyclin E2 for ubiquitin-dependent proteolysis.
Klotz K, Cepeda D, Tan Y, Sun D, Sangfelt O, Spruck C
Exp Cell Res. 2009 Jul 1;315(11):1832-9
Cyclin-dependent kinase-associated proteins Cks1 and Cks2 are essential during early embryogenesis and for cell cycle progression in somatic cells.
Martinsson-Ahlzén HS, Liberal V, Grünenfelder B, Chaves SR, Spruck CH, Reed SI
Mol Cell Biol. 2008 Sep;28(18):5698-709
The Fbxw7/hCdc4 tumor suppressor in human cancer.
Tan Y, Sangfelt O, Spruck C
Cancer Lett. 2008 Nov 18;271(1):1-12
FBXW7/hCDC4 is a general tumor suppressor in human cancer.
Akhoondi S, Sun D, von der Lehr N, Apostolidou S, Klotz K, Maljukova A, Cepeda D, Fiegl H, Dafou D, Dofou D, Marth C, Mueller-Holzner E, Corcoran M, Dagnell M, Nejad SZ, Nayer BN, Zali MR, Hansson J, Egyhazi S, Petersson F, Sangfelt P, Nordgren H, Grander D, Reed SI, Widschwendter M, Sangfelt O, Spruck C
Cancer Res. 2007 Oct 1;67(19):9006-12
The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling.
Malyukova A, Dohda T, von der Lehr N, Akhoondi S, Akhondi S, Corcoran M, Heyman M, Spruck C, Grandér D, Lendahl U, Sangfelt O
Cancer Res. 2007 Jun 15;67(12):5611-6
View All Publications
Charles Spruck's Research Focus
Cancer, Breast Cancer, Lung Cancer, Prostate Cancer
Dr. Spruck’s laboratory is focused on defining the molecular networks that regulate cell division control and how alterations of these processes contribute to the initiation and progression of cancers. An emphasis of the laboratory is protein degradation through the ubiquitin-dependent proteolysis pathway. There is also a primary focus on breast cancer. The laboratory utilizes biochemical approaches as well as in vitro and animal model systems for these studies. Current projects in the laboratory include: 1) Functional characterization of the F-box protein family, which are substrate targeting components of the SCF ubiquitin ligase enzymes, in cell division control and tumorigenesis; 2) Defining the molecular regulation(s) of cell division control protein cyclin E1 and uncovering mechanisms of dysregulation in cancers; 3) Understanding how cell division and apoptosis signaling pathways integrate to influence the response of cancer cells to chemotherapy; and 4) Developing novel methodologies based on protein microarray technology to profile changes in enzymatic activities that associate with tumorigenesis and define novel molecular targets for therapy.
About Charles Spruck
Experience
Charles Spruck earned his Ph.D. in molecular biology at the University of Southern California in 1995. He worked as a postdoctoral fellow at The Scripps Research Institute in La Jolla and was recruited to the Sidney Kimmel Cancer Center in San Diego as an Assistant Professor in 2003. He joined the Sanford-Burnham Medical Research Institute in 2010.
|
|
|
|
|
|